Cuprina Holdings (Cayman) Ltd Dossier
Qualitative Analysis
Business overview
Cuprina Holdings (Cayman) Limited is an early-stage biomedical and biotechnology company incorporated in the Cayman Islands and headquartered in Singapore. The company is dedicated to the development and commercialization of innovative products for chronic wound management and cosmeceuticals. Its flagship product line, marketed under the MEDIFLY brand, consists of medical-grade sterile blowfly larvae (Lucilia cuprina) bio-dressings used as a biological debridement tool for non-healing chronic wounds. Additionally, Cuprina is developing advanced collagen-based dressings (sponges, particles, and hydrogels) derived from the valorization of bullfrog skin waste, as well as medical leech therapies.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Leveraging the newly acquired FDA 510(k) clearance for MEDIFLY Maggots™ (Lucilia cuprina) alongside the licensed Lucilia sericata (Medical Maggots™) from Dr. Ronald Sherman to establish a unique dual-species commercial position in the U.S. wound-care market.
Expected impact: Establishes a regulatory monopoly as the only company holding FDA commercial rights to both major maggot species used in debridement therapy, allowing tailored geographic and clinical positioning.
Secured exclusive licensing rights to Southeast Asia's first medical waste recycling technology developed under the oversight of UNIDO and GEF. The technology uses high-temperature steam treatment to sterilize and recycle biohazardous waste into high-value resins.
Expected impact: Enables transition from toxic incineration to a sustainable, circular model, capturing growth in the regional medical waste management market across Singapore and up to ten other Southeast Asian countries.
Completed construction and obtained ISO 13485 certification and a dealer license for an IVF media production facility in Singapore to manufacture specialized nutrient solutions for fertility treatments.
Expected impact: Diversifies the company's biomedical portfolio beyond wound care into the high-growth infertility sector.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
To develop, test, and market Aiodine's novel iodine-based disinfectant solution as a treatment for chronic and acute wounds, antiseptics, and personal care, with clinical studies planned to commence in 2026.
Terms: Joint venture agreement signed in November 2025; specific financial terms not disclosed.
Secured an exclusive license for Dr. Sherman's 2004 FDA clearance of Lucilia sericata Medical Maggots™ for the U.S. market, and appointed Dr. Sherman as Medical and Scientific Director to oversee clinical training and regulatory affairs.
Terms: Agreement signed in July 2025, effective September 2025; financial terms not disclosed.